| Overview |
| bs-0738r-pe-100ul |
| Livin Polyclonal Antibody, PE Conjugated |
| WB |
| Human, Mouse, Rat |
| Dog, Cow |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Livin |
| 101-200/298 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 79444 |
| Q96CA5 |
| Cytoplasm, Nucleus |
| KIAP; LIVIN; MLIAP; RNF50; ML-IAP; Baculoviral IAP repeat-containing protein 7; Kidney inhibitor of apoptosis protein; Melanoma inhibitor of apoptosis protein; RING finger protein 50; BIRC7; UNQ5800/PRO19607/PRO21344 |
| Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz